Clinical Trial Update: Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib [Phase 2]

View source ↗

Summary

Phase 2 trial update on ponatinib in adults with imatinib-resistant chronic-phase chronic myeloid leukemia, describing its activity and safety profile.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Iclusig (ponatinib)

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Status: TERMINATED